{"id":"surfactant-and-air-placebo","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL2108889","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Surfactant and air placebo mimics the physical administration of a respiratory treatment without delivering an active pharmaceutical agent. It serves as a control arm in clinical studies to differentiate true drug effects from placebo effects and natural disease progression in respiratory conditions.","oneSentence":"This is a placebo control consisting of surfactant and air used in clinical trials to establish baseline comparisons for respiratory interventions.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:10:15.420Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Placebo control in respiratory disease trials"}]},"trialDetails":[{"nctId":"NCT01039285","phase":"PHASE4","title":"Exogenous Surfactant in Very Preterm Neonates in Prevention of Bronchopulmonary Dysplasia","status":"COMPLETED","sponsor":"Jean Michel Hascoet","startDate":"2009-12","conditions":"Infant, Premature, Diseases, Respiratory Distress Syndrome, Newborn, Bronchopulmonary Dysplasia","enrollment":118},{"nctId":"NCT03959384","phase":"PHASE3","title":"Efficacy and Safety of Curosurf® in Patients Invasively Ventilated for Severe Bronchiolitis Under 12 Months of Age","status":"TERMINATED","sponsor":"Azienda Ospedaliera Universitaria Integrata Verona","startDate":"2019-01-09","conditions":"Bronchiolitis, Viral","enrollment":9},{"nctId":"NCT00883532","phase":"PHASE4","title":"Prevention of Chronic Lung Disease (CLD) in Preterm Infants","status":"UNKNOWN","sponsor":"China Medical University, China","startDate":"2009-04","conditions":"Respiratory Distress Syndrome, Chronic Lung Disease of Prematurity","enrollment":300},{"nctId":"NCT00215540","phase":"PHASE2","title":"SURFAXIN® Treatment for Prevention of Bronchopulmonary Dysplasia (BPD) in Very Low Birth Weight (VLBW) Infants.","status":"TERMINATED","sponsor":"Windtree Therapeutics","startDate":"2005-02","conditions":"Respiratory Distress Syndrome, Newborn, Premature Birth, Bronchopulmonary Dysplasia","enrollment":136},{"nctId":"NCT00578734","phase":"PHASE2","title":"Lucinactant for Treatment of Acute Hypoxemic Respiratory Failure in Children up to Two Years Old","status":"COMPLETED","sponsor":"Windtree Therapeutics","startDate":"2007-06","conditions":"Acute Hypoxemic Respiratory Failure","enrollment":165}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":47,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["survanta"],"phase":"marketed","status":"active","brandName":"surfactant and air (placebo)","genericName":"surfactant and air (placebo)","companyName":"China Medical University, China","companyId":"china-medical-university-china","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is a placebo control consisting of surfactant and air used in clinical trials to establish baseline comparisons for respiratory interventions. Used for Placebo control in respiratory disease trials.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}